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Abstract: Dihydrofolate reductase (DHFR) catalyzes the reduction of dihydrofolate to tetrahydrofolate (THF). THF is 
needed for the action of folate-dependent enzymes and is thus essential for DNA synthesis and methylation. The impor-
tance of this reaction is demonstrated
 by the effectiveness of antifolate medications used to treat
 cancer by inhibiting 
DHFR, thereby depleting THF and slowing DNA
 synthesis and cell proliferation. Due to the pivotal role that DHFR plays 
in folate metabolism and cancer treatment, changes in the level of DHFR expression can affect susceptibility to a variety 
of diseases dependent on folate status such as spina bifida and cancer. Likewise, variability in DHFR expression can af-
fect sensitivity to anti-cancer drugs such as the folate antagonist methotrexate. Alterations in DHFR expression can be due 
to polymorphisms in the DHFR gene. Several variations have recently been described in DHFR, including promoter po-
lymorphisms, the 19-bp deletion allele and variations in 3’UTR. These polymorphisms seem to be functional, affecting 
mRNA levels through various interesting mechanisms, including regulation through RNA interference. Several groups 
have assessed the association of these polymorphisms with folate levels, risk of cancer and spina bifida as well as the out-
come of diseases treated with MTX. The latter may lead to different treatment schedules, improving treatment efficacy 
and/or allowing for a reduction in drug side effects. This review will summarize present knowledge regarding the predic-
tive potential of DHFR polymorphisms in disease and treatment. 
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INTRODUCTION 
  Dihydrofolate reductase (DHFR) is a member of the re-
ductase enzyme family, which is ubiquitously expressed in 
all organisms. At the transcriptional level, DHFR is gov-
erned by a TATA-less promoter that is controlled by numer-
ous transcription factors, including Sp1 and E2F that are 
important for its regulation throughout the cell cycle [1, 2]. 
Levels of this enzyme peak at the G1/S cell cycle boundary. 
Autoregulation, through DHFR-RNA interactions, has also 
been reported [3, 4]. DHFR catalyzes the NADPH-
dependent reduction of dihydrofolate (DHF) to tetrahydrofo-
late (THF) needed for several one-carbon transfer reactions 
in purine and pyrimidine synthesis [2]. DHFR is also needed 
for the intracellular conversion of synthetic folic acid, con-
sumed in supplements and fortified foods, into the THF 
forms that can participate in folate/homocysteine metabo-
lism. Reduction of DHFR enzymatic activity diminishes the 
THF pool inside the cell affecting the level of folate coen-
zymes and thus purine and pyrimidine synthesis [1].  This 
may as well influence homocysteine levels and methylation 
processes, since methyl-THF is needed for the remethylation 
of homocysteine to methionine, thereby ensuring the provi-
sion of S-adenosylmethionine (SAM) necessary for most 
biological methylation reactions [5]. DHFR inhibition is   
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essential to the action of antifolate medications used to treat 
cancer and some inflammatory diseases [6-9].  
 The  DHFR gene family includes the functional DHFR 
gene and four other intronless pseudogenes (DHFRP1–4) 
[10]. The functional gene is located at chromosome 5q11.2-
13.2 and is expressed in three mRNA isoforms with alterna-
tively spliced 3’UTR ends [11]. The changes in DHFR ex-
pression or activity can be partly due to the functional poly-
morphisms in the DHFR gene, thereby influencing a risk of 
folate-dependent diseases. Importantly, gene variations may 
also affect therapeutic responses to antifolates, leading to 
lower treatment efficacy or higher adverse drug event fre-
quency. This review will summarize several studies that ana-
lyzed whether DHFR gene polymorphisms may affect dis-
ease susceptibility or antifolate treatment outcomes. 
DHFR POLYMORPHISMS AND DISEASE SUSCEP-
TIBILITY 
  Neural tube defects (NTD) are a group of common birth 
defects with a prevalence of approximately 1 per 1,000 in 
Europe [12]. It is well documented that low serum folate and 
high homocysteine levels are associated with an increased 
risk of NTD, explaining the preventive effect of folic acid 
supplement [13, 14]. Change in activity of the folate cycle 
enzymes may affect the folate levels and affect NTD devel-
opment. It is, therefore, not surprising that polymorphisms of 
folate-dependent enzymes of both mother and child, such as 
methylene tetrahydrofolate reductase (MTHFR), have been Dihydrofolate Reductase Gene Variations in Susceptibility to Disease  Current Genomics, 2010, Vol. 11, No. 8    579 
shown to contribute to the risk of NTD [15, 16]. Neural tube 
closure occurs during a period of rapid cellular proliferation 
and DHFR activity may be a crucial factor in maintaining 
optimal DNA synthesis during this time [13]. The most ex-
tensively studied DHFR polymorphism is a 19bp insertion to 
deletion in the first intron that has been evaluated as a risk 
factor for NTD in several studies (Table 1). Johnson et al., 
2004 [17], suggested that the deletion (del) allele could af-
fect gene expression, since the Sp1 transcription factor bind-
ing site is located within the deleted sequence. The first, a 
small case-control study, provided evidence that the risk of 
having a child with spina bifida is higher for women with the 
DHFR 19bp del/del genotype than it is for those with the 
remaining genotypes [17]. The same authors [18] reported a 
higher risk of pre-term delivery in patients with the del al-
lele. Van der Linden et al., 2007 [19], reported an absence of 
association between del/del genotype and spina bifida risk, 
whereas Parle-McDermott et al., 2007 [13], observed a 
lower risk of having a child with NTD in women with the del 
allele. It has also been reported that individuals with the 
del/del genotype have lower homocysteine [20] and in-
creased serum and red blood cell folate levels [14]. A non-
significant increase in mRNA levels for homozygous del 
individuals [13], and subsequently a significant increase in 
DHFR expression with the number of del allele [21], were 
reported. This would support the possible maternal protec-
tive role of the 19-bp del allele in NTD by increasing the 
amount of DHFR available to reduce DHF to THF. How-
ever, others reported an absence of association between del 
allele and mRNA levels [19] or even suggested in the recent 
cross-sectional, population-based study [22] that the del/del 
genotype resulted in a diminished capacity of the enzyme to 
reduce folic acid. 
  It seems that the role of DHFR polymorphisms in NTD 
risk still remains to be determined, since results regarding 
19bp del allele are inconclusive. The abrogation of the Sp1 
binding site by the deletion allele or its close location to the 
splice donor site (60bp) may suggest a functional role of this 
polymorphism, yet contradictory results have been obtained. 
The other polymorphisms that are in linkage disequilibrium 
(LD) with 19bp insertion to deletion variation may be re-
sponsible for the observed results or discrepancies. Indeed, 
the high extent of LD was noted in the DHFR gene with 
19bp insertion to deletion being in LD with the promoter 
polymorphisms [23]. The same polymorphism is shared 
among several haplotypes, showing the necessity of estimat-
ing the impact based on the analysis of both individual po-
lymorphisms and haplotypes. In some instances the haplo-
types may provide more precise information for predicting 
disease risk than individual polymorphisms [24].  
  DHFR is an important folate cycle enzyme required for 
nucleic acid synthesis as well as homocysteine remethyla-
tion, suggesting that DHFR polymorphisms may play a role 
in cancer susceptibility as well. It is possible that similarly to 
MTHFR, the DHFR gene variations may play a dual role. 
Polymorphisms associated with a higher expression of 
DHFR may protect against cancer, due to the higher levels of 
5,10-methylene-THF needed for thymydylate synthesis, 
whereas a change in the 5-methyl-THF pool may affect 
methylation reactions and, consequently, increase cancer 
risk. Both genomic DNA hypomethylation and gene-specific 
promoter CpG island hypermethylation are important epige-
netic mechanisms of carcinogenesis [5, 25]. Indeed, a protec-
tive role of the DHFR 19 bp del allele in adult acute lym-
phoblastic leukemia (ALL) patients has been reported [26], 
which was further potentiated when the del allele was com-
bined with the TT677 genotype of MTHFR, previously 
shown in several studies to reduce the risk of ALL [27, 28].  
  Analysis of the DHFR 19-bp insertion to deletion poly-
morphism in relation to breast cancer susceptibility did not 
reveal a significant association with overall breast cancer 
risk [21, 29]. However, when analyses were performed fol-
lowing stratification according to multivitamin use [21], an 
association appeared significant in patients that used the 
multivitamin supplements. Individuals with the del/del geno-
type had a 50% increase in breast cancer
 risk compared with 
individuals without this genotype [21]. Although several 
cohort studies
 suggested that higher folate intake was associ-
ated with lower
 breast cancer risk, a recent large screening 
trial showed that higher supplement intake may increase the 
risk of breast cancer in postmenopausal women [30]. The 
authors [30]  further hypothesize that, because of the com-
plexity of folate function, it is possible that both deficiency 
and abundance of folate may contribute
  to breast carcino-
genesis at different stages of tumor development
 or in differ-
ent tumor phenotypes.  
  It is thus possible that genetic variations along with die-
tary intake of folate and methionine influence cellular one-
carbon metabolism and methyl-donor status, which may also 
affect susceptibility to other cancers such as colorectal carci-
noma. Recent studies have shown the potential relationship 
between germline variants in methyl-group metabolism 
genes and promoter CpG island methylation in colorectal 
tumors [31], which seems to be a specific molecular pathway 
for colon
  carcinogenesis. Curtin et al. [32] looked into an 
association among genetic polymorphisms relevant
 to folate-
mediated one-carbon metabolism, including DHFR  19-bp 
insertion to deletion polymorphism and colon cancer risk,
 but 
did not find any association with the del allele [32]. In con-
trast, a large population-based study that analyzed 395 tag 
SNPs (a sufficient number of polymorphisms to define 
common haplotypes, as based on LD) in 15 folate-pathway 
genes identified two tag SNPs in the DHFR gene (intronic 
rs1677693 A to C and rs1643659 A to G polymorphisms) 
associated with lower colorectal cancer risk [33]. The ana-
lyzed population was on a folate fortified diet, but the ob-
served protective effect was particularly obvious in non–
multivitamin supplement users, confirming previous obser-
vations that the effect of folate cycle gene variants may be 
potentiated or abrogated by dietary folate intake.  
DHFR GENE POLYMORPHISMS AND RESPONSE 
TO TREATMENT 
  The same gene variations that favor THF accumulation 
may both protect against cancer establishment (as shown in 
ALL patients [26]) and affect antifolate treatment being re-
sponsible for individual differences in terms of survival. This 
paradoxical dual and opposite effect was recently described 
as ‘‘false-friend allele’’ behavior [26], and has also been 
previously noted for MTHFR variant alleles [34]. Higher 
DHFR activity and THF accumulation can contradict a cyto-580    Current Genomics, 2010, Vol. 11, No. 8  Askari and Krajinovic 
toxic effect of antifolates, thereby reducing treatment effi-
cacy. Methotrexate (MTX) is an important antifolate widely 
used in the treatment of several malignancies, including 
acute lymphocytic leukemia, non-Hodgkin's lymphoma, os-
teosarcoma and choriocarcinoma [35]. DHFR, as a major 
MTX target, plays an important role in the development of 
MTX resistance in ALL. In both experimental and clinical 
settings, altered levels of DHFR and/DHFR gene amplifica-
tion were found in relapsed leukemia patients and in leuke-
mia and colon cell lines manifesting MTX-resistant pheno-
types [8, 36-38]. Of note is that several mechanisms may 
contribute to the development of MTX resistance. This re-
view is, nevertheless, limited only to DHFR gene variations 
and other mechanisms are reviewed in detail elsewhere [9].  
  Regarding the potential role of DHFR polymorphisms in 
response to MTX treatment (Table 1), Goto et al., 2001 [39], 
described one of the first variations in DFHR while analyz-
ing the 3-untranslated region (UTR) of the human DHFR 
gene transcript. They discovered C829T substitution located 
223 base pairs downstream from the stop codon and posi-
tioned between the first and second polyadenylation site. 
This polymorphism seems to influence DHFR expression, 
which increased with the number of T alleles being highest 
in TT individuals [39]. Consequently, the C829T-associated 
increase in DHFR expression may reduce MTX-related cyto-
toxicity. Indeed, reduction in sensitivity to MTX driven by 
this polymorphism was subsequently documented by Mishra 
et al., 2007 [40], who further elucidated the functional role 
of this variation. They showed that this SNP is located near 
the microRNA (miR)-24 3' UTR binding site and that it af-
fects DHFR expression by interfering with miR-24 function. 
Analysis in vitro using Chinese hamster ovary derived cell 
lines that lack DHFR showed that the cells with the T allele 
bind miR-24 less efficiently, resulting in a 2-fold increase in 
DHFR mRNA half-life and, hence, higher DHFR mRNA 
and protein levels. This in turn affected sensitivity to MTX. 
The cells with the T allele were 4-fold more resistant to 
MTX as compared with cells without this allele [40]. It is 
known that miRNAs play an important role in different bio-
logical processes, such as cell proliferation, cell death, stress 
resistance and fat metabolism through the regulation of gene 
expression [41]. They may also be differentially expressed in 
human cancers or may act as oncogenes and tumor suppres-
sors by targeting key regulators of cell growth [42, 43]. 
Moreover, translational control mediated by miRNAs plays 
an important role in the mechanism of cellular resistance to 
anti-cancer drug treatment [44]. The work by Mishra et al. 
[40, 45, 46] was the first to show that genetic polymorphisms 
may affect drug sensitivity acting through this mechanism. 
Several groups reported that C829T is non-polymorphic (or 
appears with very low minor allele frequency) in Caucasians 
[13, 20]. Nevertheless, it would be worth verifying whether 
this is also true at the transcriptional level and does not result 
from the difficulty in designing the primers for DNA ampli-
fication (i.e., pseudogenes and repetitive elements).  
  Changes in the level of DHFR expression and conse-
quently in sensitivity to MTX can be also due to the genetic 
polymorphisms located in the promoter. The polymorphisms 
in the 2 kb region upstream of the first or minor transcription 
initiation site (corresponding to the minor DHFR promoter) 
were recently analyzed in a cohort of childhood ALL patients 
[23]. Association of individual polymorphisms and resulting 
haplotypes with ALL outcome revealed that a reduction in 
relapse-free survival was associated with A and C  alleles 
located at positions 317 and 1610 upstream from a minor 
transcription initiation site, respectively. The association was 
also noted with the haplotype harboring these alleles, arbi-
trarily named haplotype *1. Haplotype *1 conferred higher 
transcriptional activity, as shown by reporter gene assay and 
quantitative mRNA analysis, likely explaining a worse prog-
nosis in patients carrying this haplotype. In addition to the 
minor promoter, the human DHFR gene also has a down-
stream major promoter [3, 4]. This adjacent regulatory re-
gion is located between minor and major transcript initiation 
sites and has been shown to act as a non-coding interfering 
transcript, controlling the transcription of productive mRNA 
from the major promoter [4]. The polymorphisms of this 
region were recently defined [24]  and tagging variations 
were subsequently analyzed in the same group of ALL pa-
tients [24]. The haplotype analysis revealed diversification of 
haplotype *1 [23] into five subtypes, and only one of those, 
*1b, was responsible for the lower relapse-free survival ob-
served in ALL patients, defining more precisely the relapse 
predisposing variations of DHFR. This association seems to 
be confined to patients with high-risk of relapse, as defined 
by classical clinical prognostic criteria, and it was further 
validated in an additional cohort of ALL patients. The *1b 
subtype was characterized by a particular allele combination 
defined by allele T and A at positions 35 and 308 from the 
first transcription initiation site, respectively, compound 
length polymorphisms composed of 9bp insertion at position 
63 and triple 9bp element at position 91. The 9bp repeat 
element of the compound length polymorphism was initially 
observed by Fujii et al. [47] and resembles that described in 
DHFR 5’UTR [19] and a mismatch repair gene (hMSH3) 
overlapping  DHFR  [48], although the sequence alignment 
and the number of repeats were to a certain extent differently 
resolved. Importantly, *1b was the only haplotype *1 sub-
type associated with higher mRNA levels and was predicted 
in silico to affect the structure of the major promoter [24]. It 
has been shown [3, 4] that the DHFR repression is regulated 
by a non-coding interfering transcript and that this regulation 
is due to the formation of a stable complex between non-
coding RNA, which also acquires a different conformation, 
and the major promoter. It is, thus, possible that the *1b 
haplotype could affect the function of the non-coding tran-
script, resulting in an observed increase in mRNA levels and 
a higher risk of ALL relapse [24]. 
  Low-dose MTX is considered the ‘gold standard’ of ther-
apy for rheumatoid arthritis (RA) patients [49]. Nevertheless, 
there is considerable inter-individual variation in its clinical 
efficacy. A substantial number of patients do not respond to 
treatment, whereas others (10-30%) develop drug side ef-
fects requiring discontinuation of therapy [50, 51]. Wessels 
et al., 2006 [50], analyzed the association of genetic poly-
morphisms of the folate pathway with MTX efficacy, ex-
pressed as a disease activity score, and methotrexate toxicity, 
specifically respiratory, gastrointestinal, skin, mucosal and 
hepatic adverse drug events (Table 1). Among DHFR poly-
morphisms, they analyzed DHFR G-473A (rs1650697) re-
placement in 5’ UTR and DHFR A35289G (rs1232027) sub-
stitution positioned relative to the translation initiation site. 
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Table 1.  Summary of the Studies Associating DHFR Polymorphisms with Disease Susceptibility or Response to Treatment 
Location 
/Position 
Polymorphism** Impact  Related 
Disorders 
Reference 
Intron 1 
 
 
 
 
Intron 3 
 
 
 
3-UTR 
 
 
 
 
Minor promoter* 
 
 
Major promoter* 
 
 
 
 
 
Downstream to 3’ 
UTR 
 
 
3’UTR 
19-bp insertion /deletion 
 
 
 
 
A10372C (rs1677693) 
A8890G (rs1643659) 
 
 
C829T 
 
 
 
 
C-1610G or T (rs1650694) 
A-317/G (rs408626) 
 
G308A (rs1105525) 
C35T (rs1650697) 
Length polymorphism 63/91: 9-bp 
insertion deletion/ 9-bp repeat 
(rs3045983/ - ) 
 
A35289G (rs1232027) 
 
 
 
A1171T (rs7387) 
Low-serum folate/ high homocys- 
teine, change in mRNA levels 
 
 
 
unknown 
 
 
 
Interfering with miR-24 function, 
higher DHFR mRNA and protein 
levels 
 
 
 
 
 
Higher DHFR expression 
 
 
 
 
 
Unknown 
 
 
 
Unknown 
NTD 
Breast cancer 
 
 
 
Colon cancer 
 
 
 
MTX resistance 
 
 
 
 
 
 
 
Higher risk of relapse in ALL 
 
 
 
 
 
MTX efficacy in patients with 
psoriatic arthritis 
 
 
MTX efficacy in patients with 
RA 
[13, 17] 
[21] 
 
 
 
[33] 
 
 
 
[40] 
 
 
 
 
[23] 
 
 
[24] 
 
 
 
 
 
[52] 
 
 
 
[53] 
Table summarizes positive associations described in the text. Details of other analysis which did not necessarily reveal significant associations are given in the text.  
DHFR, dihydrofolate reductase; MTX, methotrexate; ALL, acute lymphoblastic leukemia; RA, rheumatoid arthritis; NTD, neural tube defects; del, deletion.  
* polymorphism in the DHFR minor and major promoter defining *1 and *1b haplotype, respectively associated with higher DHFR expression and higher risk of relapse in ALL 
patients. Position of the polymorphism is given relative to the transcription or translation initiation site, or refers to the position within indicated intron. ** rs SNP number from 
dbSNP database at National Center for Biotechnology Information (NCBI) is provided as long it is available. 
 
et al. [52] found an association of the A allele of A35289G 
polymorphism with MTX efficacy in patients with psoriatic 
arthritis. The study conducted in RA patients from northern 
India [53] addressed additional DHFR A/T polymorphism in 
3’UTR (position 1171 of mRNA, rs7387) and revealed its 
contribution to MTX efficacy only in a multivariate model 
when analyzed together with other variations of folate-
dependent enzymes. Regarding the potential functional role 
of DHFR polymorphisms selected for rheumatoid and psori-
atic arthritis study, little can be said. The G-473A variation in 
5’UTR (rs1650697) corresponds to C35T substitution (given 
relative to the forward strand and first transcription initiation 
site) described in ALL patient analysis [24]. Individually this 
polymorphism does not seem to have an impact on mRNA 
levels. However the T allele is one of the alleles of haplotype 
*1b, which, as described above [24], seems to increase 
DHFR expression. The polymorphism in 3’ UTR such as 
rs7387 [53] may potentially affect mRNA stability. How-
ever, it is not clear what the functional role [54] of the 
A35289G variation located several Kb downstream from the 
3’UTR would be (based on dbSNP data [55]). Another 
polymorphism in LD with this DHFR variation may possibly 
explain the positive association reported. 
CONCLUSION 
  DHFR is a critical folate cycle enzyme targeted by anti-
folate medication used in the treatment of cancer and rheu-
matoid arthritis. The change in DHFR expression and activ-
ity caused by genetic polymorphisms may affect an individ-582    Current Genomics, 2010, Vol. 11, No. 8  Askari and Krajinovic 
ual’s predisposition to respond to the treatment in terms of 
efficacy and drug side effects. Due to the crucial role DHFR 
plays in the conversion of DHF to THF required for nucleic 
acid synthesis and methylation reaction, DHFR gene poly-
morphisms might affect diseases dependent on folate status, 
such as cancer and spina bifida. The genotype-phenotype 
relationships have only begun to unravel. The results ob-
tained hold promise for the future. They are still scarce and 
sometimes contradictory requiring further analysis and repli-
cation. It is clear that other polymorphisms of the folate 
pathway, dietary intake and different genetic and epigenetic 
mechanisms beyond genetic polymorphisms may contribute 
toward the variability in treatment responses, the understand-
ing of which would allow such information to be used in 
disease prevention and treatment tailored to individuals. 
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